Skip to main content


University of California, Davis Breaks Ground on Aggie Square

Published 2/21/2022

The University of California, Davis broke ground in February of 2022 on Aggie Square in Sacramento. Designed by ZGF Architects, the first phase of the mixed-use district is being developed in partnership with Wexford Science + Technology and GMH Capital Partners, who will finance, construct, and own the facilities. At the heart of Aggie Square, a vibrant central plaza will offer a variety of settings for informal interaction, mobile work, and outdoor gatherings.

Read More

Leggat McCall and DLJ Plan Life Sciences Facility at Boynton Yards

Published 1/21/2022

Leggat McCall Properties and DLJ Real Estate Capital Partners are planning to construct a 353,000-sf life sciences facility in Somerville, Mass. Offering 346,000 sf of leading-edge lab space for biomedical and pharmaceutical tenants, the 11-story structure will include 7,000 sf of retail space and below-grade parking for 242 cars.

Read More

Genentech Leases Life Sciences Building at Gateway Commons

Published 12/20/2021

Genentech has agreed to a whole-building lease for a 229,000-sf life sciences facility at Gateway Commons in South San Francisco. Developed by Alexandria Real Estate Equities and Boston Properties, 751 Gateway will provide leading-edge lab and office environments for biomedical and pharmaceutical research. Featuring best-in-class amenities, the collaborative structure represents the first phase of a vibrant biomedical campus. Construction is ongoing with initial occupancy expected in early 2024. 

Read More

University of Redlands Plans Mixed-Use District

Published 12/17/2021

The University of Redlands is planning to construct the 30-acre University Village adjacent to its existing campus in Redlands, Calif. Moore Ruble Yudell has been selected as the architect and planner for the public-private development, which is being created in collaboration with REACH Redlands LLC, a joint venture of Republic MetropolitanCreative Housing Associates, and Arteco Partners.

Read More

The Davis Companies Plans Cambridge Life Sciences Facility

Published 10/18/2021

The Davis Companies is planning to construct a three-story, 161,616-rsf research facility in Cambridge, Mass. Strategically sited in a new life sciences cluster called The Quad, the purpose-built structure will provide Class A lab and office environments for biomedical and pharmaceutical firms. Features of 101 Smith Place include:

Read More

Ivanhoé Cambridge and Lendlease Plan Boston Life Sciences Facility

Published 9/13/2021

Ivanhoé Cambridge and Lendlease will break ground in summer of 2022 on a 320,000-sf life sciences facility in Boston. Designed by SGA, the nine-story building will provide state-of-the-art labs, offices, and collaboration spaces for biomedical and pharmaceutical tenants. Offering BSL-1 and BSL-2 research environments, the amenity-rich structure will include a multipurpose ground floor, a parking garage, and numerous outdoor areas.

Read More

Fitzsimons Innovation Community Breaks Ground on Cell and Gene Therapy Center

Published 9/6/2021

The Fitzsimons Innovation Community broke ground in August of 2021 on Bioscience 5 in Aurora, Colo. Strategically located next to the University of Colorado Anschutz Medical Campus, the 90,000-sf building will enable biomedical and pharmaceutical tenants to manufacture next-generation cell and gene therapy products on a commercial scale. Saunders Construction is the general contractor for the highly flexible facility, which is slated for occupancy in spring of 2022.

Read More

The Davis Companies and Boston Development Group Break Ground on Watertown Life Sciences Building

Published 9/1/2021

The Davis Companies and Boston Development Group broke ground in August of 2021 on a purpose-built life sciences building in Watertown, Mass. The joint-venture project will offer 224,000 rsf of Class A research space for biomedical and pharmaceutical tenants. Designed by Elkus Manfredi Architects, the facility will provide next-generation laboratories, offices, a fitness center, a shared rooftop balcony, six private outdoor areas, and ample indoor parking accessible directly beneath the building.

Read More

Boston Properties Breaks Ground on Waltham Life Sciences Facility

Published 8/9/2021

Boston Properties broke ground in July of 2021 on a $105 million life sciences facility in Waltham, Mass. Designed by Stantec, 180 CityPoint will provide leasable lab and office environments with exceptional access to natural light and views. Featuring shared meeting spaces and a collaborative co-working nexus, the six-story, 329,000-sf building will include an expansive roof deck, a food hall, a wellness center, an indoor basketball court, and a 900-car parking structure.

Read More

DivcoWest Constructs Life Sciences Facility at Cambridge Crossing

Published 7/9/2021

DivcoWest broke ground in June of 2021 on a 375,000-sf life sciences facility in the Cambridge Crossing innovation district. Designed by Ennead Architects with Jacobs Consultancy as the architect of record, the collaborative building will provide leading-edge research environments for biomedical and pharmaceutical tenants. Comprising ten floors of lab space, two penthouse levels, and multiple outdoor terraces, the project will offer generous ceiling heights with minimal interior columns for optimal flexibility.

Read More

Architectural Billings Continue Historic Rebound

Published 7/5/2021

Demand for design services from U.S. architecture firms continues to grow at a vigorous pace, according to a report issued by the American Institute of Architects in June of 2021. AIA’s Architecture Billings Index score for May rose to 58.5 compared to 57.9 in April. Any score above 50 indicates an increase in billings, and May’s ABI score is one of the highest in the index’s 25-year history.

Read More

AbCellera Biologics Plans Antibody Manufacturing Plant

Published 6/30/2021

AbCellera Biologics is planning to break ground in late 2021 on a manufacturing plant for therapeutic antibodies in Vancouver, British Columbia. Supported by $175.6 million in federal funding, the 130,000-sf project will cost approximately CAD$240 million to build. Offering advanced production suites, labs, offices, and warehouse space, the GMP facility will enhance the country's ability to create vaccines in response to future pandemic threats.

Read More